发明名称 PEPTIDES FOR USE IN THE TOPICAL TREATMENT OF RETINAL NEURODEGENERATIVE DISESASES, IN PARTICULAR IN EARLY STAGES OF DIABETIC RETINOPATHY AND OTHER RETINAL DISEASES IN WHICH NEURODEGENERATION PLAYS AN ESSENTIAL ROLE
摘要 The invention relates to peptides with a sequence length from 13 to 50 amino acids, the N-terminal region of said peptides consisting in the sequence HXaa1EGTFTSDXaa2SXaa3Xaa4 (SEQ ID NO: 1) wherein: Xaa1 is an amino acid selected from alanine and glycine; Xaa2 is an amino acid selected from valine and leucine; Xaa3 is an amino acid selected from serine and lysine; Xaa4 is an amino acid selected from tyrosine and glutamine; and Hystidine is the N-terminal residue; for use in the topical treatment and/or prevention of retinal neurodegenerative diseases, in particular diabetic retinopathy. The invention also encompasses pharmaceutical topical compositions for use in the topical treatment and/or prevention of these diseases.
申请公布号 US2016000882(A1) 申请公布日期 2016.01.07
申请号 US201414770067 申请日期 2014.02.27
申请人 FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA 发明人 SIMÓ CANONGE Rafael;HERNÁNDEZ PASCUAL Cristina
分类号 A61K38/26;A61K9/00;A61K38/10 主分类号 A61K38/26
代理机构 代理人
主权项 1. A method for the treatment and/or prevention of a retinal neurodegenerative disease comprising topically administering in the eye a therapeutically effective amount of a peptide, which is able to reach the retina, with a sequence length from 13 to 50 amino acids, the N-terminal region of said peptide having the sequence: HXaa1EGTFTSDXaa2SXaa3Xaa4 (SEQ ID NO: 1) wherein: Xaa1 is an amino acid selected from alanine and glycine;Xaa2 is an amino acid selected from valine and leucine;Xaa3 is an amino acid selected from serine and lysine;Xaa4 is an amino acid selected from tyrosine and glutamine; andhystidine is the N-terminal residue;together with pharmaceutically acceptable excipients and/or carriers, in a subject in need thereof, including a human.
地址 Barcelona ES